Bullous Pemphigoid

Detailed Overview

BP is the most common autoimmune blistering disease. IgG autoantibodies target the hemidesmosomal proteins BP180 and BP230 at the dermal-epidermal junction. This triggers complement activation and neutrophil infiltration, leading to subepidermal split. The blisters are tense, non-scarring, and accompanied by severe pruritus. Unlike pemphigus vulgaris, mucous membranes are rarely involved.

Epidemiology & Demographics

Incidence is 10-40 per million annually. Peak onset is in individuals over age 60, heavily skewed towards octogenarians.

Etiological Mechanism

Autoimmune production of IgG against hemidesmosomes. Triggers may include medications, trauma, or UV radiation.

Primary Causes

Primary: Idiopathic autoimmune. Secondary (drug-induced): DPP-4 inhibitors (gliptins), furosemide, penicillamine, PD-1 inhibitors.

• Advanced Age: Over 70 years of age is the primary demographic.
• Neurological Disease: Strong association with Parkinson's disease, dementia, and stroke, possibly due to BPAG1 cross-reactivity in the brain.

IgG autoantibodies bind BP180 (type XVII collagen) and BP230 in the hemidesmosomes of the basement membrane zone. This antigen-antibody complex activates the classical complement pathway. C3a and C5a recruit eosinophils and neutrophils, which release proteases (elastase, MMP-9). These enzymes degrade the hemidesmosomes, causing a subepidermal split and formation of tense, robust blisters.

Characteristic Clinical Presentation

• Severe Pruritus: Intense itching, often preceding the appearance of blisters by weeks to months (prodromal phase).
• Blister Formation: Eruption of large, tense blisters on the trunk, flexural areas, and extremities.

Physical Examination Signs

• Tense Bullae
• Negative Nikolsky Sign
• Urticarial Plaques

• Secondary Skin Infection: Erosion of blisters can lead to Staphylococcal or Streptococcal superinfection.
• Sepsis: Extensive skin barrier breakdown in elderly/immunosuppressed patients can be fatal.

Diagnostic Criteria & Guidelines

Diagnosis requires clinical presentation of tense bullae, two biopsies (one for H&E showing subepidermal cleft with eosinophils, one for DIF showing linear IgG/C3 at the basement membrane), and positive serum ELISA for BP180/BP230 autoantibodies.

Differential Diagnosis

• Pemphigus Vulgaris (flaccid blisters, mucosal involvement, +Nikolsky)
• Epidermolysis Bullosa Acquisita
• Dermatitis Herpetiformis

Laboratory Tests & Biomarkers

• Direct Immunofluorescence (DIF): Linear deposition of IgG and C3 along the dermal-epidermal junction.
• Serum ELISA: Elevated anti-BP180 (>9 U/mL) and anti-BP230 antibodies.
• CBC: Peripheral blood eosinophilia in >50% of patients.

Imaging Modalities & Findings

• None:

• Prodromal
  Pruritic, eczematous, or urticarial papules/plaques without blisters.
• Bullous
  Widespread eruption of tense vesicles and bullae with clear or hemorrhagic fluid.

Second-Line & Adjunctive Therapy

For steroid-sparing or refractory disease: Methotrexate 10-15 mg PO weekly, Mycophenolate mofetil 1-2 g/day, or Doxycycline 100 mg BID combined with Niacinamide 500 mg TID.

Surgical & Procedural Management

None. Debridement of necrotic skin may be needed if infected.

Recommended Lifestyle Changes

• Avoid friction or trauma to the skin.
• Use gentle, non-irritating soaps and apply copious emollients.

Patient Counseling & Advice

Counsel patients that the disease is chronic but can go into remission. Warn about the risks of long-term oral steroids (osteoporosis, hyperglycemia).

Follow-Up & Monitoring Schedule

Monthly visits to titrate steroid dosing based on new blister formation. Monitor DEXA scan and HbA1c if on long-term prednisone.

Preventive Strategies

Avoid known drug triggers (e.g., specific DPP-4 inhibitors like vildagliptin/linagliptin).

Generally good with treatment, often remitting after 1-5 years. However, 1-year mortality can be up to 20-30% in frail, elderly patients due to infections or steroid complications.